Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of BioScrip, Inc. Stockholders
April 06 2015 - 5:55PM
Business Wire
Kirby McInerney LLP is investigating potential claims against
the Board of Directors of BioScrip, Inc. (“BioScrip” or the
“Company”) (NASDAQ:BIOS) concerning the Company’s alleged
participation in a kickback scheme.
A U.S. Department of Justice press release issued on January 8,
2014 revealed that BioScrip agreed to forfeit $15 million for the
Company’s alleged participation in a kickback scheme with Novartis
Pharmaceuticals Corporation related to Novartis’s product Exjade®.
Furthermore, on March 31, 2015, a federal judge denied, in part, a
motion to dismiss a complaint alleging that BioScrip made
misleading statements pertaining to the distribution of
Exjade®.
If you are a BioScrip stockholder and wish to obtain additional
information, please contact J. Brandon Walker, Esq. by email
at bwalker@kmllp.com, or telephone at (212) 699-1145, Melissa
Fortunato, Esq. by email at mfortunato@kmllp.com, or telephone at
(212) 699-1141, or toll free at (888) 529-4787, or by filling out
this contact form. There is no cost or obligation to you.
Kirby McInerney LLP is a New York-based law firm concentrating
in securities, whistleblower, antitrust and consumer litigation.
For additional information, please go to www.kmllp.com.
Kirby McInerney LLPJ. Brandon Walker, Esq., (212)
699-1145bwalker@kmllp.comorMelissa Fortunato, Esq., (212)
699-1141mfortunato@kmllp.com
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Apr 2023 to Apr 2024